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Atopic dermatitis (AD) patients may benefit from using textiles coated with skin micro-
biome–modulating compounds. Chitosan, a natural biopolymer with immunomodulatory
and antimicrobial properties, has been considered potentially useful.
Objective
This randomized controlled trial assessed the clinical utility of chitosan-coated garment use
in AD.
Methods
Of the 102 patients screened, 78 adult and adolescents were randomly allocated to over-
night use of chitosan-coated or uncoated cotton long-sleeved pyjama tops and pants for 8
weeks. The primary outcome was change in disease severity assessed by Scoring Atopic
dermatitis index (SCORAD). Other outcomes were changes in quality of life, pruritus and
sleep loss, days with need for rescue medication, number of flares and controlled weeks,
and adverse events. Changes in total staphylococci and Staphylococcus aureus skin
counts were also assessed. Comparisons were made using analysis of variance supple-
mented by repeated measures analysis for the primary outcome. Interaction term between
time and intervention was used to compare time trends between groups.
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Results
Chitosan group improved SCORAD from baseline in 43.8%, (95%CI: 30.9 to 55.9), P =
0.01, placebo group in 16.5% (-21.6 to 54.6); P = 0.02 with no significant differences
between groups; Dermatology Quality of life Index Score significantly improved in chitosan
group (P = 0.02) and a significant increase of skin Coagulase negative Staphylococci (P =
0.02) was seen.
Conclusions
Chitosan coated textiles may impact on disease severity by modulating skin staphylococcal




Atopic dermatitis (AD) is a chronic, relapsing inflammatory skin disease with a considerable
social and economic burden. In industrialized countries, it has an estimated prevalence of up to
20% in children and 2% in adults [1]. Its pathophysiology is complex and involves skin barrier
defects, immunological deregulation, and genetic predisposition [2]. These changes frequently
lead to skin colonization with Staphylococcus aureus, which is able to produce virulence factors
that perpetuate inflammation, even in normal-appearing skin [3]. Disease management
demands an integrated approach, aimed not only at controlling skin inflammation and ensur-
ing hydration, but also at regulating the skin microbiome [4–6].
While several recent studies have reported the utility of functional textiles with antimicro-
bial and antipruritic properties in AD [7, 8], a recent systematic review and meta-analysis by
our group found that the recommendation for its use was weak due to the low quality of sup-
porting evidence [9]. These results underscored the need for studies with improved methodol-
ogy and new compounds. Chitosan, a biopolymer [10], has been considered a promising
candidate for use in AD due to its with repair and antiseptic properties [11–13]. Chitosan-
coated fabrics with proven inhibitory activity against S. aureus were considered potentially use-
ful in AD management, but their clinical utility on a real life setting has never been studied.
This randomized controlled clinical trial assessed the clinical utility of chitosan-coated gar-
ments in AD patients.
Methods
This is a randomized, double-blind, placebo-controlled, single-center trial. Fig 1 shows the
flow of participants. Trial registrations: ClinicalTrials.gov Identifier: NCT01597817. Protocol
Registration and Results System account administration delay in releasing the record due to
informatics issues caused that the trial was registered after enrolment of participants had
started. The authors confirm that all ongoing and related trials for this intervention are regis-
tered. Ethics committee approved the study at 6th September 2011, patients recruitment and
follow up occurred between December 2011 and June 2012.
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Recruitment
Subjects were invited to participate in the trial during hospital visits, through trial posters on
bulletin boards in hospitals, newspaper and Internet advertisements.
Inclusion and exclusion criteria
Subjects older than 12 years with a diagnosis of AD [14] were eligible for participation follow-
ing provision of written informed consent. Excluded were patients with severe skin disease
other than AD (e.g., psoriasis); secondary infections; major systemic diseases; women who
were pregnant and subjects unable to comply with study and follow-up procedures.
Patients who met any of the following criteria were withdrawn from the study: use of topical
or systemic antibiotics during the study; withdrawal of consent; detection of significant proto-
col violations; and investigator’s decision to withdraw the patient due to adverse effects such as
skin infections.
Sample size
Sample size calculations were performed to determine the number of participants needed to
detect effect sizes based on minimal clinically important differences in the SCORAD index.
Fig 1. Flow chart of participants through the study.
doi:10.1371/journal.pone.0142844.g001
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Results showed that 42 patients were needed in this two-treatment parallel-design study to
detect a treatment difference with a two-sided 0.05 significance level and a probability of 81% if
the true difference in SCORAD between interventions was 8.7 units [15].
Randomization, allocation and blinding
Subjects were randomly assigned to one of two interventions through computer-generated ran-
dom numbers. The randomization was performed by an independent researcher;the randomi-
zation table and intervention codes were kept by the independent researcher in an opaque
sealed envelope up to completion of data analysis. A study nurse established phone contact
with the independent researcher, who informed the nurse which treatment package was to be
assigned to which patient.
A hundred and two patients were assessed for eligibility; twenty-four were excluded because
they did not meet inclusion criteria: 22 because the medical diagnosis of AD was not confirmed
by the investigation team and two because of significant comorbidities (multiple sclerosis and
diabetes mellitus type 1). Seventy-eight were randomized: thirty five to placebo and forty three
to chitosan groups. In chitosan group two patients were lost before receiving the intervention
and one patient decided to withdraw because of disease progression. In both groups three
patients were lost to follow up due to impossibility to attain medical visits (Fig1).
Treatment protocol and intervention
The study consisted of a 2-week run-in period and an intervention period of 8 weeks (S1
Table). Eligibility to participate was determined at the screening visit. At the end of the run-in
period, the patients were examined by the same physician as in the first visit and those with a
change in SCORAD of below 10% with respect to baseline were considered eligible for random-
ization. Participants were randomized to receive either an uncoated pair of cotton pyjamas or a
pair of cotton pyjamas coated with chitosan (ChitoClear CG-800). The pyjamas, placed in a
sealed plastic package, consisted of a long-sleeved top and long pants to be worn at night for
the duration of the study. Both pyjamas were made of 100% organic cotton, without dyes or
preservatives, and were visually indistinguishable from each other. The in vitro antibacterial
activity of the chitosan-coated textile was shown to persist after 30 washing cycles [16] and
washing durability was studied through washing assays at 40°C [16].
Outcomes and definitions
The primary efficacy outcome measure was mean relative and absolute change in disease sever-
ity after the intervention assessed by SCORAD [14]. The SCORAD index combines objective
items reflecting disease extent, intensity and subjective items (pruritus and sleep loss) evaluated
by the patient on a 10-point visual analog scale (VAS), where 0 indicates no pruritus or sleep
loss and 10 indicates the worst possible pruritus and sleep loss. The total possible score ranges
from 0 to 103.
Secondary outcome measures were number of patients with a minimal clinically important
difference in SCORAD post-intervention; mean change in quality of life score; changes in daily
pruritus and sleep loss scores; need for rescue medication; number of flares; number of totally
controlled weeks (TCWs) and well-controlled weeks (WCWs); and number and severity of
adverse events during the 8-week study period. Microbiological outcome measures were mean
changes in colony forming units (CFUs) per 100 cm2 of total staphylococci (S. aureus plus
coagulase negative staphylococcus species) and S. aureus isolates.
Patients were characterized according to age, gender, current medication, personal history
of atopy, self-reported medical diagnosis of asthma, disease duration, and disease severity. The
Chitosan Textiles and Atopic Dermatitis
PLOS ONE | DOI:10.1371/journal.pone.0142844 November 30, 2015 4 / 14
SCORAD index was used to classify AD as mild (score15), moderate (16–39), or severe
(>40) [17]. During the baseline and final visits, participants were asked to complete the Portu-
guese version of the Dermatology Life Quality Index (DLQI) or, if they were younger than 16
years, the children´s version of the questionnaire. Both questionnaires have been translated
and validated for use in the Portuguese population [18, 19]. DLQI scores are interpreted as no
effect on the patient’s life (score of 0–1), a small effect (2–5), a moderate effect (6–10), a very
large effect (11–20), and an extremely large effect (21–30) [20, 21].
Participants recorded and scored daily symptoms of pruritus and sleep loss according to the
10-point VAS, and registered all medication use during the study period. Rescue medication
was defined as any treatment, other than emollient, applied in response to disease worsening
(i.e. escalation of treatment). A flare was defined as an episode requiring rescue medication for
3 or more consecutive days; a TCW week as a pruritus score of above 4; and a WCW as a 7-day
period with need for rescue treatment or with a sleep loss or pruritus score of above 4 for no
more than 2 days. [22].
Microbiological assays
The microbiological profile was assessed by determination of viable cell numbers of total staph-
ylococci and S. aureus in five regions: the right and left brachial crease, right and left popliteal
crease, interscapular region. The regions were assessed by sampling a 25-cm2 area of skin with
a sterile cotton swab dipped in sterile saline solution. Samples were kept refrigerated at 4°C and
were processed within a maximum of 2 hours of sampling. They were decimally diluted and
plated in Mannitol Salt agar (MSA; Lab Mspread plate) and Baird-Parker agar (BPA; Lab M,
Lancashire, UK) using the spread plate technique. After incubation, the colonies were counted,
using MSA for total staphylococcal counts and BPA for S. aureus counts, the respective Colony
Forming units /100 cm2 were determined.
Adverse events
Patients were asked to inform the research team of any possible adverse events that occurred
during the 8-week study period. Adverse events were classified as mild if they were easily toler-
ated by the patient; moderate if they interrupted the individual’s usual activities; and severe if
they were potentially life-threatening. The principal investigator classified adverse events as
not, possibly, probably, or definitely related to treatment.
Statistical analysis
All efficacy outcomes were analyzed using intent-to-treat populations based on the treatment
group assigned at randomization.
Analysis of variance (ANOVA) supplemented by a repeated measures analysis was used for
the primary outcome. A mixed effects models with random intercept and time slope by indi-
vidual were used to estimate the interaction term to compare time trends between groups for
number of days per week with need for rescue medication and daily symptoms. Chi-squared,
Fisher exact and McNemar test were used for secondary outcomes; Wilcoxon signed rank test
and MannWhitney test for non-parametric analysis; t test for parametric analysis. All analyses,
summaries, and listings were performed with SPSS software, version 20.0.
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No major imbalances were found in the baseline characteristics of the individuals included in
the placebo and chitosan groups: most patients were adult, with AD for more than 10 years,
more than half were female, the majority were atopic and had self reported previous history of
asthma (Table 1). Oral antihistamines and topical steroids were used by most patients, almost
half had been prescribed at least once oral steroids in the last year and a systemic immunosu-
pressor such as cyclopsorin in 17% overall. Similar proportion of participants with mild (2 ver-
sus 5), moderate (19 versus 14) and severe (22 versus 16) AD occurred respectively in chitosan
and placebo intervened groups.
Efficacy and tolerability. After the 8-week intervention period there was a significant
improvement in SCORAD from baseline for both the chitosan group and the placebo group
(improvement of 43.8%, 95% CI: 30.9 to 55.9; P = 0.01 vs. 16.5%, 95% CI: -21.6 to 54.6;
P = 0.02). The respective absolute reductions in SCORAD scores were from 44.2 (95% CI: 34.5
to 53.9) to 29.4 (95% CI: 21.4 to 37.4) and 41.4 (95% CI: 34.3 to 48.6) to 25.7 (95% CI: 18.3 to
33.1); (Fig 2). No significant differences were observed between groups for changes in
SCORAD.
Table 1. Baseline characteristics of atopic dermatitis patients by chitosan intervention group (N = 43) and placebo group (N = 35).
Chitosan Placebo P-value
Age, y 23 (19–34) 26 (18–31) 0.61§
Female, n (%) 23 (53) 21 (60) 0.86*
Disease duration, y 18 (10–24) 12.0 (6–20) 0.31§
SCORAD (0–103) 44 (25–52) 38 (22–65) 0.72§
Current medication
Antihistamines, n (%) 36 (84) 32 (91) 0.50*
Topical corticosteroids, n (%) 37 (86) 27 (77) 0.18*
Oral corticosteroids, n (%) 15 (35) 16 (46) 0.58*
Calcineurin inhibitors, n (%) 12 (28) 16 (46) 0.18*
Oral immunsupressors, n (%) 9 (21) 4 (11) 0.13ε
Diary scores
Pruritus (0–10) 4 (2–4) 3 (2–5) 0.92§
Sleep loss (0–10) 2 (1–4) 1 (0–3) 0.31§
DLQI score 7 (5–12) 7 (5–12) 0.93§
Atopic, n (%) 29 (70) 21 (60) 0.29*
Asthmatic, n (%) 21 (49) 18 (51) 0.69*
DLQI, Dermatology Life Quality Index. Results are presented as median (interquartile range) unless stated otherwise.
§ Mann Whitney test.
* Chi-squared test
ε Fisher exact test.
doi:10.1371/journal.pone.0142844.t001
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The improvement in DLQI scores from baseline was 36% (95% CI: 23.5 to 48.1) in the chit-
osan group (8.0 [9.3–6.7] to 4.8 [6.2–3.4], P = 0.02) and 25% (95% CI: 6.0–44.1) in the placebo
group (8.3 [10.4–6.3] to 5.6 [7.7–3.5], P = 0.28) (Fig 2). There were no significant differences
between both groups. The proportion of individuals with a clinically meaningful improvement
in SCORAD was 25 (67%) in the chitosan group and 20 (63%) in the placebo group. No signifi-
cant effect was observed either on daily pruritus or sleep loss scores (Fig 3 and S2 Table), need
for rescue medication, or number of flares or totally controlled weeks and well controlled
weeks (Table 2).
Most patients had identification of Staphylococci species in at least one sampled region with
no significant changes after the intervention or for changes between groups (Table 3). There a
was a decrease in the percentage of patients with identification of S.aureus from 68% to 55% in
chitosan group in contrast with an increase in placebo group (from 53% to 64%) that did not
reach statistical significance (Table 3). The mean proportion of S.aureus counts versus total
staphylococcal counts showed no significant differences after intervention for both groups on
the five sample regions (right arm, left arm, right leg, left leg, neck) (Table 3) neither when con-
sidering all regions (Fig 4). When considering total bacterial counts there was a significant
increase of the mean total staphylococcal count in the chitosan group (P = 0.02), with no other
differences (Fig 5).
The chitosan-coated pyjamas were well tolerated. One patient in the chitosan group decided
to withdraw at week 4 due to an AD flare, but no causal link was established.
Discussion
In this randomized controlled trial chitosan coated textiles, used for 8 weeks, were associated
with a non-significant trend of disease severity improvement. Moreover, this effect was related
with a significant increase of skin coagulase negative Staphylococci.
Our study has some limitations. First, since this is a pilot study the number of participants
and outcomes assessed may have been not sufficient to detect significant differences. However,
Fig 2. Mean SCORAD and Dermatology Life Quality Index scores (95% CI) in chitosan and placebo groups before and after intervention. CI-
confidence interval.
doi:10.1371/journal.pone.0142844.g002
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Fig 3. Mean (95%CI) weekly pruritus and sleep loss scores in chitosan and placebo groups throughout the intervention period.CI-confidence
interval.
doi:10.1371/journal.pone.0142844.g003
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based on previously published minimally clinically important differences for SCORAD, the
study was designed to be sufficiently powered to detect meaningful differences. However, post
hoc analysis analysing the high range of confidence limits in the control group versus the active
one suggested this may have not been the case. Although we only used validated outcomes in
line with recently published recommendations [23], DLQI did not fit Rasch analysis in previ-
ous studies [24] and its children´s version has not been tested till now. Nevertheless it has been
previously validated in Portuguese population[19] and in our study we found an intraclass cor-
relation coefficient in placebo group of 0.73 signifying a good reproducibility. Second, the
study participants were adolescents and adults with long-standing atopic dermatitis and there
would probably be a greater likelihood of detecting clinically significant improvement in adults
with more severe disease. Thirdly, because no a priori data exist on the duration of the inter-
vention and its in vivo effects, we cannot rule out that longer skin contact with chitosan may
have elicited a more pronounced effect. However, the participants were instructed to wear the
Table 2. Differences in efficacy outcomes in chitosan and placebo groups after intervention.
Chitosan Placebo P-value for difference§
Rescue medication, days 2.0 (0.0–8.3) 5.0 (0.0–15.5) 0.82
Flares 0.0 (0.0–1.0) 0.0 (0.0–1.0) 0.73
Totally controlled weeks 4.0 (0.8–7.0) 4.5 (1.8–8.0) 0.43
Well controlled weeks 1.5 (0.8–3.0) 2.0 (0.0–3.0) 0.82
Uncontrolled weeks 1.0 (0.0–4.3) 1.0 (0.0–5.0) 0.94
Median (interquartile range)
§ Mann Whitney test.
Rescue medication defined as any treatment, other than emollient, that was applied in response to a worsening of the disease, corresponding to dosing
up treatment; a flare as need of rescue medication for three or more consecutive days; a totally controlled week as a seven-day period without need of
rescue treatment and without any days of sleep loss or pruritus score above 4; a well controlled week if rescue treatment and sleep loss or pruritus score
above 4 occurred for no more than 2 days, and any other week that did not correspond to the previous definitions of totally and well controlled weeks was
classified as no controlled;
doi:10.1371/journal.pone.0142844.t002
Table 3. Skin microbiological profile in chitosan and placebo groups before and after intervention.
Chitosan Placebo Chitosan vs Placebo
Before (N = 38) After (N = 34) P-value Before (N = 30) After (N = 28) P-value P-value
Staphylococci +, n (%) of patients 34 (85) 30 (75) 0. 71 P 26 (87) 23 (82) 0.92 P 0.68Φ
S. aureus +, n (%) of patients 27 (68) 22 (55) 0.92 P 18 (53) 18 (64) 0.72 P 0.69.Φ
% CFU S. aureus/total staphylococci
Right arm 58 (14–74) 55 (18–68) 0.43* 71 (38–94) 81 (31–96) 0.21* 0.14§
Left arm 62 (12–68) 61 (12–77) 0.94* 65 (38–81) 67 (39–70) 0.42* 0.34 §
Right leg 66 (18–73) 65 (13–76) 0.32* 68 (22–78) 67 (22–89) 0.52* 0.92 §
Left leg 70 (18–82) 69 (25–77) 0.91* 69 (24–78) 71 (36–88) 0.83* 0.73 §
Neck 58 (22–71) 42 (22–61) 0.11* 74 (21–80) 76 (29–92) 0.34* 0.93 §
CFU, colony-forming units. Median (interquartile range) unless stated otherwise.
P McNemar test
Φ Chi-squared test
* Wilcoxon signed rank test
§ Mann Whitney test.
doi:10.1371/journal.pone.0142844.t003
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pyjamas every night for the duration of the study, as we wished to target a critical period.
Finally, the fact that the patients were allowed to use rescue medication may have influenced
the effect of the intervention. However, this was corrected for in the mixed effects model and
the effect on clinical outcome analyses should therefore be minimal. This is the first trial to
evaluate the utility of a biopolymer in patients with AD and, so far, it is the largest study of
functional textiles. Another innovative aspect was the evaluation of other staphylococcal spe-
cies than S.aureus [25].
Chitosan has exhibited skin repair potential in wounds and antimicrobial action in diverse
medical fields [26–29], explaining why chitosan could potentially improve disease severity in
patients prone to non-commensal bacteria colonization and skin barrier impairment. In the
present study, chitosan-coated garments had no effect on the skin S.aureus counts but surpris-
ingly, we observed in the chitosan group an increase in total staphylococci counts indepen-
dently of S. aureus, corresponding to coagulase negative staphylococci species (CNS). The
Fig 4. Mean (95%CI) Staphylococcus aureus colony forming units in all regions as proportion of total staphylococcal counts before and after
intervention in placebo and chitosan groups. CI-confidence interval.
doi:10.1371/journal.pone.0142844.g004
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increase of CNS on the skin of AD patients has been already reported eliciting different expla-
nations for this fact: some authors argue that it may be the result of a mutualistic relationship
or represent a compensatory or antagonistic mechanism to control S.aureus [30]. Our data
supports the hypothesis that chitosan may had exerted a specific inhibitory effect upon S.
aureus, allowing the proliferation of other staphylococcal species. Nevertheless, the clinical sig-
nificance of this observation is exploratory.
The observed placebo effect on disease severity may possibly be due to the improved skin
comfort provided by the long-sleeved organic cotton pyjamas used, and/or to the patients’
enthusiasm about participating in a clinical trial with a new product.
The significant improvement on quality of life with chitosan treatment was probably related
to reduction in AD severity in this group. Considering that sample size was calculated to detect
Fig 5. Mean (95%CI) Log10 total staphylococci and Log10 Staphylococcus aureus counts for all regions sampled in chitosan and placebo groups
before and after intervention. CI-confidence interval *P = 0.01, Wilcoxon signed rank test.
doi:10.1371/journal.pone.0142844.g005
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changes in SCORAD index, we cannot exclude that more patients were needed to elicit a more
pronounced effect on this outcome.
The intervention was well tolerated over the 8-week study period. There was one moderate
adverse event, deemed to be unrelated to treatment, in the chitosan group. Safety of functional
textiles is a controversial issue since some authors have claimed that the use of antimicrobial
compounds could remove bacteria from the skin surface and pave the way for invasion by
pathogenic bacteria, such as methicillin-resistant S. aureus [31].
Atopic dermatitis is a complex disease that requires a multidimensional treatment
approach. The possibility of modulating the skin microbiome, namely its staphylococcal com-
munity, which has long been recognized as one of the main determinants of skin inflammation,
is an appealing strategy. The use of functional textiles is also appealing because of their poten-
tial action targeting the skin surface and their favourable safety profile and convenience of use.
Results from our randomized controlled trial showed that chitosan coated textiles may impact
on disease severity by modulating skin staphylococcal profile. Moreover, a potential effect in
quality of life may be considered.
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